Perspectives on NcRNAs in HBV/cccDNA-driven HCC progression
- PMID: 40544269
- PMCID: PMC12182653
- DOI: 10.1186/s12935-025-03849-0
Perspectives on NcRNAs in HBV/cccDNA-driven HCC progression
Abstract
Hepatitis B virus (HBV) integration, the HBx protein (and its mutants), and covalently closed circular DNA (cccDNA) are critical for HBV replication, packaging, and transmission to new host cells. Although nucleos(t)ide analogs (NAs) are a class of antiviral drugs that effectively suppress HBV replication, they do not eliminate cccDNA. This persistent cccDNA, often referred to as an "invisible bullet", plays a pivotal role not only in the horizontal transmission of HBV but also within the context of hepatocellular carcinoma (HCC). Growing evidence reveals that noncoding RNAs (ncRNAs) are deeply involved in cancer progression, as well as the HBV life cycle and related pathogenesis, including liver inflammation, fibrosis, and HCC. This involvement occurs through various mechanisms, as ncRNAs regulate gene transcription, act as miRNA sponges, modulate signaling pathways, and influence downstream effects. These functions depend on the proper formation of RNA structures, which are critical for maintaining the biological activity of ncRNAs. The structure of RNAs appears to play a pivotal role in their functional capacity. Moreover, both ncRNAs and viral nucleotides contribute to G-quadruplex structure formation, which is essential for the HBV life cycle and cancer progression. In this review, we provide an updated overview of the mechanisms by which key ncRNAs mediate HBV/cccDNA actions in HCC progression and focus on their roles in gene expression and structural formation/modification.
Keywords: Cancer progression; CccDNA; Epigenetic regulation; G-quadruplex; HBV; HBx; HCC; NcRNAs; Nucleos(t)ide analogue; Paraspeckle.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures



Similar articles
-
Therapeutic interventions aimed at cccDNA: unveiling mechanisms and evaluating the potency of natural products.Front Cell Infect Microbiol. 2025 Jun 17;15:1598872. doi: 10.3389/fcimb.2025.1598872. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40599653 Free PMC article. Review.
-
Lamin A/C promotes HBV transcription by modulating histone modification associated with cccDNA minichromosome in an HBx-dependent manner.Virol J. 2025 Jun 11;22(1):189. doi: 10.1186/s12985-025-02820-9. Virol J. 2025. PMID: 40500754 Free PMC article.
-
CRISPR-mediated proximity labeling unveils ABHD14B as a host factor to regulate HBV cccDNA transcriptional activity.Hepatol Commun. 2025 Jul 14;9(8):e0757. doi: 10.1097/HC9.0000000000000757. eCollection 2025 Aug 1. Hepatol Commun. 2025. PMID: 40658808 Free PMC article.
-
NIH Consensus Statement on Management of Hepatitis C: 2002.NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714
-
Discovery and mechanistic study of Imperatorin that inhibits HBsAg expression and cccDNA transcription.J Med Virol. 2024 May;96(5):e29669. doi: 10.1002/jmv.29669. J Med Virol. 2024. PMID: 38773784
References
-
- Zoulim F, Chen PJ, Dandri M, Kennedy PT, Seeger C. Hepatitis B virus DNA integration: implications for diagnostics, therapy, and outcome. J Hepatol. 2024;81(6):1087–99. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources